Palovarotene - Clementia Pharmaceuticals
Alternative Names: Clm-001; IPN-60120; R-667; RAR-gamma; RG-667; RO-3300074; SohonosLatest Information Update: 13 Feb 2024
At a glance
- Originator Roche
- Developer Clementia Pharmaceuticals; Ipsen; Roche
- Class Benzoic acids; Eye disorder therapies; Naphthalenes; Pyrazoles; Small molecules
- Mechanism of Action Retinoic acid receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fibrodysplasia ossificans progressiva
- Discontinued Bone disorders; Dry eyes; Emphysema
Most Recent Events
- 08 Feb 2024 Launched for Fibrodysplasia ossificans progressiva (In adolescents, In children, In adults) in USA (PO), before February 2024
- 28 Nov 2023 Registered for Fibrodysplasia ossificans progressiva (In adolescents, In children, In adults) in Australia (PO)
- 26 Oct 2023 Ipsen announces intention to launch Palovarotene in USA